Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tenapanor + midazolam
- Development stage
- Phase 1
- Lead developer
- Ardelyx
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**tenapanor + midazolam** is a combination of tenapanor (also known as AZD1722 and RDX5791), a small molecule sodium/hydrogen exchanger 3 (NHE3) inhibitor developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and hyperphosphatemia in chronic kidney disease, with midazolam, an oral benzodiazepine commonly used as a probe substrate for CYP3A4 drug-drug interaction studies. Tenapanor works primarily by inhibiting intestinal NHE3, reducing sodium absorption, and increasing intestinal water content, improving stool frequency and abdominal symptoms in IBS-C. The combination is not a marketed product; it is used specifically in clinical pharmacology studies to evaluate the impact of tenapanor on CYP3A4 activity, using changes in midazolam pharmacokinetics to assess possible drug-drug interactions[3][5][1].
- Brand names
- Ibsrela + midazolam
- Other names
- sodium/hydrogen exchanger 3 inhibitor + midazolam
02
Targets
NHE3 (Sodium/hydrogen exchanger 3)GABRA1 (Gamma-aminobutyric acid type A receptor alpha 1 subunit)
Beyond the preview
Go deeper on tenapanor + midazolam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tenapanor + midazolam.